Among patients with non-small cell lung cancer (NSCLC) treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes. This was the conclusion of a phase I clinical trial presented at the Annual Meeting of the American Association for Cancer Research(AACR) being held in San Diego, CA, USA,April 5-9, 2014
Preliminary data from the trial, which were reportedearlier this year at the AACR-IASLC Joint Conference on the
Molecular Origins of Lung Cancer (January 6-9, 2014; San Diego), showed that MK-3475 treatment was well tolerated and led todurable, objective responses in previously treated patients with NSCLC, particularly those with tumors found to have high levels of PD-L1 prior to treatment.
The latest results extend these data, showing that at six months after starting treatment, 41% of patients whose tumors had high levels of PD-L1 had no disease progression, compared with 17% of those whose tumors had low levels of PD-L1. Similarly, 72% of patients whose tumors had high levels of PD-L1 were alive at this time, compared with 53% of those whose tumors had low levels of PD-L1.
This data strongly suggest that high levels of tumor PD-L1 may be a good biomarker for determining which patients with NSCLC are most likely to benefit from treatment with MK-3475
?Patients with previously treated NSCLC have a very poor outlook and there is a real need for newtreatment options,” notedLeena Gandhi, M.D., Ph.D., assistant professor of medicine atHarvard Medical Schoolin Boston. ?The responses we have seen among patients whose tumors express high levels of PD-L1 appear to be quite durable, which is extremely exciting.
?Immune cells called T cells are naturally capable of destroying cancer cells,? explained Gandhi, who is also a thoracic oncologist at theDana-Farber Cancer Institute. ?But some cancer cells are able to prevent T cells from attacking them by activating the T cells? ?brakes.? One way they do this is via a protein called PD-L1 on their surface, which attaches to a protein on the surface of T cells, PD-1. MK-3475 disables this brake by blocking PD-1 on the T cells and preventing it from attaching to PD-L1.?
Gandhi and colleagues enrolled patients with NSCLC to multiple cohorts on the phase I clinical trial. When they analyzed the data based on pretreatment tumor PD-L1 levels, information they were able to obtain for 146 patients, it was found that levels of PD-L1 of greater than 50%, as measured by immunohistochemistry, served as the best cutoff point for differentiating outcomes for PD-L1-positive versus PD-L1-negative tumors. For the group of 41 patients with high pretreatment tumor PD-L1 levels, response rate was 37% as compared with 11% for those with low pretreatment tumor PD-L1 levels.
Strong data
?These data strongly suggest that high levels of tumor PD-L1 may be a good biomarker for determining which patients with NSCLC are most likely to benefit from treatment with MK-3475,? said Gandhi. ?We will present outcome data on this full group of patients who have now had PD-L1 expression analyzed. These results extend our findings from the initial 38 patients, and an ongoing, randomized study will prospectively evaluate the role of PD-L1 expression in determining outcome to MK3475 versus docetaxel therapy.?
This study was funded by Merck. Gandhi declares no conflicts of interest.
Photo:Leena Gandhi, M.D., Ph.D.,Photo Courtesy:Harvard Medical Schoolin Boston, MA, USA.
Copyright ? 2014 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent ofInPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
